{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:35:02Z","timestamp":1776389702980,"version":"3.51.2"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universitat de Valencia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Extragonadal germ cell tumors (EGCT) are rare malignancies, typically located in midline structures, with treatment consisting of cisplatin-based chemotherapy. We aimed to evaluate long-term outcomes, identify prognostic factors and assess treatment efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively evaluated 31 patients with EGCT between 1994 and 2024. RStudio was used for data analysis. Progression free survival (PFS) and overall survival (OS) was assessed using Kaplan\u2013Meier, and prognostic factors via Cox regression. Approval was obtained from our local Ethics Committee.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The most common site was mediastinum (59%), followed by retroperitoneum and central nervous system. Non-seminomatous germ cell tumors (NSGCT) were more frequent than seminomas (61% vs. 39%), and 41% of patients had metastasis at diagnosis. After first-line chemotherapy plus selective surgery or irradiation, the disease control rate was 81%. Progression or relapse occurred in 48% of patients, mostly in those with mediastinal NSGCT. No secondary malignancies were detected during follow-up. 5- and 10-year OS were 70%. NSGCT histology and mediastinal location were significantly associated with lower survival, with a 5-year OS of 34% in mediastinal NSGCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>While cisplatin-based chemotherapy remains effective for EGCT patients, mediastinal NSGCT pose significant challenges, highlighting the need for improved strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12094-025-03904-2","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:51:18Z","timestamp":1745992278000},"page":"4058-4063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term survival and prognostic factors in extragonadal germ cell tumors: a 30-year experience at a single institution"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6803-8228","authenticated-orcid":false,"given":"Patricia","family":"Capdevila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristobal","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Escriv\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Aparicio Urtasun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"3904_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1365-2605.2011.01245.x","volume":"35","author":"A Stang","year":"2012","unstructured":"Stang A, Trabert B, Wentzensen N, Cook MB, Rusner C, Oosterhuis JW, et al. Gonadal and extragonadal germ cell tumours in the United States, 1973\u20132007. Int J Androl. 2012;35:616\u201325.","journal-title":"Int J Androl"},{"key":"3904_CR2","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.3390\/ijms22115982","volume":"22","author":"M De Felici","year":"2021","unstructured":"De Felici M, Klinger FG, Campolo F, Balistreri CR, Barchi M, Dolci S. To be or not to be a germ cell: the extragonadal germ cell tumor paradigm. Int J Mol Sci. 2021;22:5982.","journal-title":"Int J Mol Sci"},{"key":"3904_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2605.2007.00793.x","volume":"30","author":"JW Oosterhuis","year":"2007","unstructured":"Oosterhuis JW, Stoop H, Honecker F, Looijenga LH. Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. Int J Androl. 2007;30:256\u201363.","journal-title":"Int J Androl"},{"key":"3904_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/PAP.0b013e31803240e6","volume":"14","author":"JK McKenney","year":"2007","unstructured":"McKenney JK, Heerema-McKenney A, Rouse RV. Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol. 2007;14:69\u201392.","journal-title":"Adv Anat Pathol"},{"key":"3904_CR5","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2002.07.062","volume":"20","author":"C Bokemeyer","year":"2002","unstructured":"Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol. 2002;20:1864\u201373.","journal-title":"J Clin Oncol"},{"key":"3904_CR6","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s12094-024-03532-2","volume":"26","author":"JA Arranz Arija","year":"2024","unstructured":"Arranz Arija JA, Del Muro XG, Caro RL, M\u00e9ndez-Vidal MJ, P\u00e9rez-Valderrama B, Aparicio J, et al. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023). Clin Transl Oncol. 2024;26:2783\u201399.","journal-title":"Clin Transl Oncol"},{"key":"3904_CR7","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2017.73.4723","volume":"31","author":"T Tandstad","year":"2017","unstructured":"Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. J Clin Oncol. 2017;31:3525\u20138.","journal-title":"J Clin Oncol"},{"key":"3904_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/1097-0142(19930915)72:6<1894::AID-CNCR2820720617>3.0.CO;2-6","volume":"72","author":"EM Dulmet","year":"1993","unstructured":"Dulmet EM, Macchiarini P, Suc B, Verley JM. Germ cell tumors of the mediastinum. a 30-year experience. Cancer. 1993;72:1894\u2013901.","journal-title":"Cancer"},{"key":"3904_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/cncr.11068","volume":"97","author":"S Takeda","year":"2003","unstructured":"Takeda S, Miyoshi S, Ohta M, Minami M, Masaoka A, Matsuda H. Primary germ cell tumors in the mediastinum. a 50-year experience at a single Japanese institution. Cancer. 2003;97:367\u201376.","journal-title":"Cancer"},{"key":"3904_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/10668969231201413","volume":"32","author":"MD Sekar","year":"2024","unstructured":"Sekar MD, Pradeep I, Srinivas BH, Kayal S. Extragonadal germ cell tumors: a single institution experience with clinicopathological correlation. Int J Surg Pathol. 2024;32:865\u201374.","journal-title":"Int J Surg Pathol"},{"key":"3904_CR11","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1002\/cncr.27403","volume":"118","author":"RS Arora","year":"2012","unstructured":"Arora RS, Alston RD, Eden TOB, Geraci M, Birch JM. Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003. Cancer. 2012;118:4290\u20137.","journal-title":"Cancer"},{"key":"3904_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1023\/A:1008225129682","volume":"8","author":"M Hidalgo","year":"1997","unstructured":"Hidalgo M, Paz-Ares L, Rivera F, Lianes P, Huidobro G, Ruiz A, et al. Mediastinal non-seminomatous germ cell tumours (MNSGCT) treated with cisplatin-based combination chemotherapy. Ann Oncol. 1997;8:555\u20139.","journal-title":"Ann Oncol"},{"key":"3904_CR13","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1002\/cncr.35375","volume":"130","author":"NH Richardson","year":"2024","unstructured":"Richardson NH, Taza F, Abonour R, Althouse SK, Ashkar R, Abu Zaid M, et al. High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience. Cancer. 2024;130:3115\u201322.","journal-title":"Cancer"},{"key":"3904_CR14","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.20.03292","volume":"39","author":"J Beyer","year":"2021","unstructured":"Beyer J, Collette L, Sauv\u00e9 N, Daugaard G, Feldman DR, Tandstad T, International Germ Cell Cancer Classification Update Consortium, et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium. J Clin Oncol. 2021;39:1553\u201362.","journal-title":"J Clin Oncol"},{"key":"3904_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/COC.0000000000000959","volume":"45","author":"D Aguiar Bujanda","year":"2022","unstructured":"Aguiar Bujanda D, P\u00e9rez Cabrera D, Croissier SL. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: a surveillance, epidemiology, and end results-based study. Am J Clin Oncol. 2022;45:493\u2013500.","journal-title":"Am J Clin Oncol"},{"key":"3904_CR16","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.23.01960","volume":"42","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, Le Teuff G, Fl\u00e9chon A, Pagliaro L, Mardiak J, Geoffrois L, et al. Personalized chemotherapy on the basis of tumor marker decline in poor-prognosis germ-cell tumors: updated analysis of the GETUG-13 Phase III trial. J Clin Oncol. 2024;42:3270\u20136.","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03904-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03904-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:48:39Z","timestamp":1758721719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03904-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["3904"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03904-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained by the local Ethics Committee of our center (Drug Research Ethics Committee La Fe).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required for this study, given its nature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}